New treatment options for patients with metastatic colorectal cancer

Erin Grothey, Axel F Grothey

Research output: Contribution to journalArticle

Abstract

With approval by the US Food and Drug Administration in September, panitumumab will emerge as yet another option available to community oncologists for treating patients with advanced, refractory colorectal carcinoma (CRC). Panitumumab's antitumor activity stems from its ability to target and interfere with epidermal growth factor receptor (EGFR) signaling. The drug is potentially interchangeable with cetuximab in chemotherapeutic regimens. But integrating panitumumab into existing treatment strategies for advanced CRC will present a challenge for community oncologists, as the drug's best application in this disease setting is not yet clear. This article sets the stage for the supplement, first providing a summary of EGFR-targeted therapies, a description that contrasts cetuximab with panitumumab, and a discussion of the pivotal clinical trials of panitumumab in CRC.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalCommunity Oncology
Volume3
Issue number10 SUPPL. 4
StatePublished - Oct 2006

Fingerprint

Colorectal Neoplasms
Epidermal Growth Factor Receptor
Therapeutics
United States Food and Drug Administration
Pharmaceutical Preparations
panitumumab
Clinical Trials
Oncologists
Cetuximab

ASJC Scopus subject areas

  • Oncology

Cite this

Grothey, E., & Grothey, A. F. (2006). New treatment options for patients with metastatic colorectal cancer. Community Oncology, 3(10 SUPPL. 4), 3-9.

New treatment options for patients with metastatic colorectal cancer. / Grothey, Erin; Grothey, Axel F.

In: Community Oncology, Vol. 3, No. 10 SUPPL. 4, 10.2006, p. 3-9.

Research output: Contribution to journalArticle

Grothey, E & Grothey, AF 2006, 'New treatment options for patients with metastatic colorectal cancer', Community Oncology, vol. 3, no. 10 SUPPL. 4, pp. 3-9.
Grothey, Erin ; Grothey, Axel F. / New treatment options for patients with metastatic colorectal cancer. In: Community Oncology. 2006 ; Vol. 3, No. 10 SUPPL. 4. pp. 3-9.
@article{dbd43ba289b54b189a5d7097a46d911d,
title = "New treatment options for patients with metastatic colorectal cancer",
abstract = "With approval by the US Food and Drug Administration in September, panitumumab will emerge as yet another option available to community oncologists for treating patients with advanced, refractory colorectal carcinoma (CRC). Panitumumab's antitumor activity stems from its ability to target and interfere with epidermal growth factor receptor (EGFR) signaling. The drug is potentially interchangeable with cetuximab in chemotherapeutic regimens. But integrating panitumumab into existing treatment strategies for advanced CRC will present a challenge for community oncologists, as the drug's best application in this disease setting is not yet clear. This article sets the stage for the supplement, first providing a summary of EGFR-targeted therapies, a description that contrasts cetuximab with panitumumab, and a discussion of the pivotal clinical trials of panitumumab in CRC.",
author = "Erin Grothey and Grothey, {Axel F}",
year = "2006",
month = "10",
language = "English (US)",
volume = "3",
pages = "3--9",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "10 SUPPL. 4",

}

TY - JOUR

T1 - New treatment options for patients with metastatic colorectal cancer

AU - Grothey, Erin

AU - Grothey, Axel F

PY - 2006/10

Y1 - 2006/10

N2 - With approval by the US Food and Drug Administration in September, panitumumab will emerge as yet another option available to community oncologists for treating patients with advanced, refractory colorectal carcinoma (CRC). Panitumumab's antitumor activity stems from its ability to target and interfere with epidermal growth factor receptor (EGFR) signaling. The drug is potentially interchangeable with cetuximab in chemotherapeutic regimens. But integrating panitumumab into existing treatment strategies for advanced CRC will present a challenge for community oncologists, as the drug's best application in this disease setting is not yet clear. This article sets the stage for the supplement, first providing a summary of EGFR-targeted therapies, a description that contrasts cetuximab with panitumumab, and a discussion of the pivotal clinical trials of panitumumab in CRC.

AB - With approval by the US Food and Drug Administration in September, panitumumab will emerge as yet another option available to community oncologists for treating patients with advanced, refractory colorectal carcinoma (CRC). Panitumumab's antitumor activity stems from its ability to target and interfere with epidermal growth factor receptor (EGFR) signaling. The drug is potentially interchangeable with cetuximab in chemotherapeutic regimens. But integrating panitumumab into existing treatment strategies for advanced CRC will present a challenge for community oncologists, as the drug's best application in this disease setting is not yet clear. This article sets the stage for the supplement, first providing a summary of EGFR-targeted therapies, a description that contrasts cetuximab with panitumumab, and a discussion of the pivotal clinical trials of panitumumab in CRC.

UR - http://www.scopus.com/inward/record.url?scp=33845635074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845635074&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33845635074

VL - 3

SP - 3

EP - 9

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 10 SUPPL. 4

ER -